• Ellen M. Lavoie Smith, PhD, MSN, RN, AOCN®, FAAN, is a Professor, Assistant Dean for Research and Scholarship, and the Marie O’Koren Endowed Chair at the University of Alabama at Birmingham (UAB) School of Nursing. Dr. Smith has lectured nationally and internationally regarding multiple cancer-related topics and has published 90 peer-reviewed manuscripts. Her research is well recognized as pioneering and pivotal in identifying interventions for chemotherapy-induced peripheral neuropathy (CIPN), a life-altering complication of neurotoxic chemotherapy for which no known treatments have been discovered. She has received independent extramural research funding from the National Institutes of Health (NIH) and foundation and industry sponsors. Her research revealed duloxetine efficacy for painful CIPN (JAMA, 2013). As a result, duloxetine is remains the only treatment for painful CIPN recommended by the American Society of Clinical Oncology (JCO, 2020). Further, she has led multiple instrument development studies involving both adults and children with CIPN. She currently leads an NCI/R01-funded Phase II-III trial to test duloxetine to prevent CIPN through the Alliance NCI-funded Cooperative Group network. As recognition for her pioneering work, Dr. Smith has received numerous national awards including the 2018 Fellows of the National Institute of Nursing Research Welch/Woerner Path Paver Award.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2023 Physical Activity Programming for Older Adults in Assisted Living: Residents’ PerspectivesWestern Journal of Nursing Research.  45:105-116. 2023
    2023 Comparison of Pre-Diagnosis Physical Activity and Its Correlates between Lung and Other Cancer Patients: Accelerometer Data from the UK Biobank Prospective CohortInternational Journal of Environmental Research and Public Health.  20. 2023
    2022 Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxelBreast Cancer Research and Treatment.  194:551-560. 2022
    2022 Physical activity in surgical lung cancer patients: a systematic reviewSupportive Care in Cancer.  30:6473-6482. 2022
    2022 Efficacy of the Motivational Interviewing-Walk Intervention for Chemotherapy-Induced Peripheral Neuropathy and Quality of Life During Oxaliplatin Treatment: A Pilot Randomized Controlled Trial.Cancer Nursing.  45:E531-E544. 2022
    2022 Temporal, Location-and Symptom-Specific Likelihood of Patient-Reported Sensory Symptoms Related to Oxaliplatin-Induced Peripheral Neuropathy (OIPN) in Patients Receiving Oxaliplatin for Three MonthsCancers.  14. 2022
    2021 Comparative assessment of ActiGraph data processing techniques for measuring sedentary behavior in adults with COPDPhysiological Measurement.  42. 2021
    2021 Acceptance and Use of Home-Based Electronic Symptom Self-Reporting Systems in Patients With Cancer: Systematic Review. 2021
    2021 Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIVAIDS.  35:407-417. 2021
    2021 Characteristics and patterns of pediatric chemotherapy-induced peripheral neuropathy: A systematic reviewCancer Treatment and Research Communications.  28. 2021
    2020 Acceleration of relativistic beams using laser-generated terahertz pulsesNature Photonics.  14:755-759. 2020
    2020 Darunavir Pharmacokinetics With an Increased Dose During Pregnancy 2020
    2020 Fosamprenavir with ritonavir pharmacokinetics during pregnancyAntimicrobial Agents and Chemotherapy.  64. 2020
    2019 Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire–Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study dataSupportive Care in Cancer.  27:2599-2608. 2019
    2019 Pharmacokinetics of Increased Nelfinavir Plasma Concentrations in Women During Pregnancy and PostpartumJournal of Clinical Pharmacology.  59:386-393. 2019
    2019 Sertraline pharmacokinetics in HIV-infected and uninfected children, adolescents, and young adultsFrontiers in Pediatrics.  7. 2019
    2018 Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIVAIDS.  32:2507-2516. 2018
    2016 Etravirine pharmacokinetics in HIV-infected pregnant womenFrontiers in Pharmacology.  7. 2016
    2016 Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women 2016
    2015 Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant WomenClinical Infectious Diseases.  61:1582-1589. 2015
    2015 Pharmacokinetics of tenofovir during pregnancy and postpartumHIV Medicine.  16:502-511. 2015
    2015 Measurement of the lifetime of the Bc+ meson using the Bc+→J/ψπ+ decay mode 2015
    2015 Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: The Pediatric AIDS Clinical Trials Group Protocol 1020A 2015
    2015 Measurement of the CP-violating phase β in B0→J/ψπ+π- decays and limits on penguin effects 2015
    2015 Measurement of the Z+b-jet cross-section in pp collisions at(Formula presented.)= 7 TeV in the forward region 2015
    2015 Measurement of the inelastic pp cross-section at a centre-of-mass energy of √s = 7 TeV 2015
    2015 Search for the lepton flavour violating decay τ → μμ+μ 2015
    2015 Study of η − η mixing from measurement of B (s)0 → J/ψη(′) decay rates 2015
    2014 Measurement of the B0B0 and Bs 0Bs 0 production asymmetries in pp collisions at √s = 7TeV 2014
    2014 LHCb CollaborationNuclear Physics A.  932:621-626. 2014
    2014 Measurement of CP violation and constraints on the CKM angle γ in B±→DK± with D→KS0π+π- decaysNuclear Physics B.  888:169-193. 2014
    2014 First observations of the rare decays B+ → K+π+π-μ+μ- and B+ → φK+μ+μ- 2014
    2014 First observations of the rare decays B+ → K+π+π-μ+μ- and B+ → φK+μ+μ- 2014
    2014 Measurement of CP asymmetries in the decays B0 → K*0μ+μ− and B+ → K+μ +μ− 2014
    2014 Effective lifetime measurements in the Bs0→K+K-, B0→K+π-and B0s→π+K-decays 2014
    2014 Measurement of the CP-violating phase φs in B-s0→J/ψπ+π- decays 2014
    2014 Measurement of the Ξb- and Ωb- baryon lifetimes 2014
    2014 Observation of Z production in proton-lead collisions at LHCb 2014
    2014 Observation of Z production in proton-lead collisions at LHCb 2014
    2014 Study of (Formula presented.) production and cold nuclear matter effects in pPB collisions at (Formula presented.) TeV 2014
    2014 Precision measurement of the ratio of the Λb0 to B-0 lifetimes 2014
    2014 A study of CP violation in B ±→DK ± and B ±→Dπ ± decays with D→KS0K±π∓ final states 2014
    2014 Evidence for the decay B+c → J/ψ3π+- 2014
    2014 Study of beauty hadron decays into pairs of charm hadronsPhysical Review Letters.  112. 2014
    2014 Angular analysis of charged and neutral b → kμ+μ− decays 2014
    2014 Measurement of CP asymmetries in the decays B0 → K*0μ+μ− and B+ → K+μ+μ−Critical Ultrasound Journal.  2014:1-18. 2014
    2014 Measurement of CP asymmetries in the decays B0 → K*0μ+μ and B+ → K+μ+μ 2014
    2014 Measurement of cp asymmetries in the decays b0 → k*0μ+μ- and b+ → k+μ+μ- 2014
    2014 Measurement of polarization amplitudes and cp asymmetries in B0 → φK∗(892)0 2014
    2014 Measurement of the ckm angle γ using b± → dk± with d → ks π+π−, ks k+k− decays 2014
    2014 Measurement of the forward W boson cross-section in pp collisions at (Formula presented.)TeV 2014
    2014 Measurement of the xb(3p) mass and of the relative rate of xb1(1p) and xb2(1p) production 2014
    2014 Measurement of Υ production in pp collisions at √s = 2.76 TeV 2014
    2014 Observation of associated production of a Z boson with a D meson in the forward region 2014
    2013 Reduced indinavir exposure during pregnancyBritish Journal of Clinical Pharmacology.  76:475-483. 2013
    2013 Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy 2013
    2013 Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.Journal of the American Medical Association.  309:1359-1367. 2013
    2012 Effect of pregnancy on emtricitabine pharmacokineticsHIV Medicine.  13:226-235. 2012
    2012 Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum 2012
    2011 Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescentsAIDS.  25:1489-1496. 2011
    2011 Atazanavir pharmacokinetics with and without tenofovir during pregnancy 2011
    2011 Rapid intrapartum or postpartum HIV testing at a midwife obstetric unit and a district hospital in South AfricaInternational Journal of Gynecology and Obstetrics.  113:44-49. 2011
    2010 Lopinavir tablet pharmacokinetics with an increased dose during pregnancy 2010
    2009 Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai womenAntimicrobial Agents and Chemotherapy.  53:2189-2191. 2009
    2008 Lopinavir exposure with an increased dose during pregnancy 2008
    2008 Adherence to antiretrovirals among US women during and after pregnancy 2008
    2008 Mitomycin C potentiates ultraviolet-related cytotoxicity in corneal fibroblasts.Cornea.  27:686-692. 2008
    2008 Chronic administration of nevirapine during pregnancy: Impact of pregnancy on pharmacokineticsHIV Medicine.  9:214-220. 2008
    2008 Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) protocol 353HIV Clinical Trials.  9:115-125. 2008
    2008 Nevirapine concentrations in newborns receiving an extended prophylactic regimen 2008
    2008 Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 Week resultsAIDS.  22:249-255. 2008
    2007 Long-term observation of adolescents initiating HAART therapy: Three-year follow-upAIDS Research and Human Retroviruses.  23:1208-1214. 2007
    2007 Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant womenAntimicrobial Agents and Chemotherapy.  51:783-786. 2007
    2006 Reduced lopinavir exposure during pregnancyAIDS.  20:1931-1939. 2006
    2006 Impact of pregnancy on abacavir pharmacokineticsAIDS.  20:553-560. 2006
    2005 Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load responseJournal of Infectious Diseases.  192:296-302. 2005
    2005 GB virus C infection in children with perinatal human immunodeficiency virus infection 2005
    2004 Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocolJAMA Pediatrics.  158:1007-1013. 2004
    2004 Long term tolerability and safety af enfuvirtide for human immunodeficiency virus 1-infected children 2004
    2003 Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infectionPediatrics.  112:66-73. 2003
    2001 Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants 2001
    1975 Identification of a novel heptaglycosylceramide with two fucose residues and a terminal hexosamine 1975
    1975 Characterization of Dog Small Intestinal Fucolipids with Human Blood Group H ActivityBiochemistry.  14:3370-3376. 1975
    1975 Main structures of the forssman glycolipid hapten and a leb-like glycolipid of dog small intestine, as revealed by mass spectrometry. Difference in ceramide structure related to tissue localization 1975
    1975 Characterization by Mass Spectrometry of Blood Group A Active Glycolipids from Human and Dog Small IntestineBiochemistry.  14:2120-2124. 1975
    1974 Correlation of Canine Secretory Alloantigens A and Y with Two Fucolipids Isolated from Dog IntestinesExperimental Biology and Medicine.  147:883-886. 1974
    1973 Human blood group activity of human and canine intestinal glycolipids containing fucoseImmunology.  25:621-629. 1973
    1973 The subcellular distribution of glycolipids of dog intestinal mucosaThe Alabama journal of medical sciences.  10:417-422. 1973
    1973 Structural and immunological studies on dog and human intestinal fucolipids 1973
    1972 Separation of dog intestine glycolipids into classes according to sugar content by thin-layer chromatography: Evidence for individual dog intestine specific glycolipidsAnalytical Biochemistry.  45:608-616. 1972

    Teaching Overview

  • Dr. Smith's record as an educator provides strong evidence of sustained excellence in teaching, including experience with advanced students. Her commitment to the teaching mission is evidenced by excellence in classroom teaching, and by deep and effective mentoring of highly successful undergraduate, doctoral, and post-doctoral students. Prior to her hire at the UAB School of Nursing, she served as the PhD Program Director at the University of Michigan School of Nursing. Her creative and inclusive leadership led to exciting innovations within the University of Michigan PhD program. Now as the Assistant Dean for Research and Scholarship and Marie O'Koren Endowed Chair at the UAB School of Nursing, she contributes to UAB's teach mission by establishing infrastructure to support faculty scholarship. She co-leads the Office of Research and Scholarship’s Faculty Scholar and Mentor Service Unit. This unit is establishing Scholarship Collaboratives--groups of early to senior career faculty with common interests in research, teaching, and clinical scholarship, who work together to produce enhanced scholarship. This Service Unit also provides faculty scholars with access to robust mentorship and support via educational seminars and lecture which build faculty skills. Over the years, she has served as the PI for several pre-doctoral training grants (e.g., American Cancer Society, Robert Wood Johnson, Jonas Foundation). Currently, she serves as the dual PI for the NIH-funded Cancer Prevention and Control T32 Training Program (T32CA047888). This grant provides support for 8 trainees per year (4 pre- and 4 postdoctoral) to expand their knowledge in cancer prevention and control research and to promote their success as future independent cancer research scientists.
  • Education And Training

  • Doctor of Philosophy in Nursing Science, University of Utah 2008
  • Master of Nursing in Registered Nursing / Registered Nurse, University of New Hampshire 1991
  • Bachelor of Nursing in Registered Nursing / Registered Nurse, University of Vermont 1982
  • Full Name

  • Ellen Smith